Oral immunomodulation therapy in rheumatoid arthritis.;L'immunomodulation par voie orale dans la polyarthrite

Revue du Rhumatisme (Edition Francaise)

Volumn 67, Issue 8, 2000, Pages 593-603

  Meyer, Olivier ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Arthrite juv nile; Chronic juvenile arthritis; Collagen II; Collag ne II; Nasal tolerance; Oral tolerance; Polyarthrite rhumato de; Rheumatoid arthritis; TGF ; Th3; Tol rance; Tol rance nasale; Tol rance orale

Indexed keywords

EID: 0041409947     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1169-8330(00)00020-x     Document Type: Article

References (53)

1. Brandtzaeg P. History of oral tolerance and mucosal immunity. Oral tolerance, mechanisms and applications. Ann NY Acad Sci. 778:1996;1-27.
2. Weiner H.L. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today. 19:1997;335-343.
3. Chen Y.H., Weier H.L. Dose-dependent activation and deletion of antigen-specific T cells following oral tolerance. Ann NY Acad Sci. 778:1996;111-121.
4. Xiao B.G., Link H. Mucosal tolerance: a two-edged sword to prevent and treat autoimmune disease. Clin Immunol Immunopathol. 85:1997;119-128.
5. Kerneis S., Bogdanova A., Kraehenbuhl J.P., Pringault E. Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria. Science. 277:1997;949-952.
6. Berlin C., Berg E.L., Briskin M.J., Andrew D.P., Kilshaw P.J., Holzmann B., et al. α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 74:1993;185-195.
7. Lazarovits A.I., Karsh J. Differential expression in rheumatoid synovium and synovial fluid of α4β7 integrin. J Immunol. 151:1993;6482-6489.
8. Chen Y., Inobe J.I., Marks R., Gonnella P., Kuchroo V.K., Weiner H.L. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature. 375:1995;177-180.
9. Husby S., Mestecky J., Moldoveanu Z., Holland S., Elson C.O. Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J Immunol. 152:1994;4663-4670.
10. Khoury S.J., Hancock W.W., Weiner H.L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and factor β, interleukin 4 and prostaglandin E expression in the brain. J Exp M. 176:1992;1355-1364.
11. Weiner H.L., Friedman A., Miller A., Khoury S.J., Al-Sabbagh A., Santos L., et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Ann Rev Immunol. 12:1994;809-837.
12. Strobel S., Mowat A.M. Immune responses to dietary antigens: oral tolerance. Immunol Today. 19:1998;173-181.
13. Campbell N., Yio X.Y., So L.P., Li Y., Mayer L. The intestinal epithelial cell: processing and presentation of antigen to the mucosal immune system. Immunol Rev. 172:1999;315-324.
14. Williamson E., O'Malley J.M., Viney J.L. Visualising the T-cell response elicited by oral administration of soluble protein antigen. Immunology. 97:1999;565-572.
15. Viney J.L., Mowat A.M., O'Malley J.M., Williamson E., Fanger N.A. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J Immunol. 160:1998;5815-5825.
16. Vistica B.P., Chanaud N.P., Felix N., Caspi R.R., Rizzo L.V., Nussenblatt R.B., Gery I. CD8 T-cells are not essential for the induction of « low-dose » oral tolerance. Clin Imunol Immunopathol. 78:1996;196-202.
17. Karpus W.J., Kennedy K.J., Kunkel S.L., Lukacs N.W. Monocyte chemotactic protein 1 regulates oral tolerance induction by inhibition of T helper cell 1-related cytokines. J Exp M. 187:1998;733-741.
18. Ke Y., Pearce K., Lake J.P., Ziegler H.K., Kapp J.A. γδ T lymphocytes regulate the induction and maintenance of oral tolerance. J Immunol. 158:1997;3610-3618.
19. Lefrançois L. Intraepithelial lymphocytes of the intestinal mucosa: curiouser and curiouser. Semin Immunol. 3:1991;99-107.
20. Fujihashi K., Dohi T., Kweon M.N., Mcghee J.R., Koga T., Cooper M.D., et al. Gammadelta T cells regulate mucosally induced tolerance in a dose-dependent fashion. Int Immunol. 11:1999;1907-1916.
21. Fujihashi K., Taguchi T., Aicher W.K., McGhee J.R., Bluestone J.A., Eldridge J.H., et al. Immunoregulatory functions for murine intraepithelial lymphocytes γ/δ T cell receptor-positive (TCR+) T cells abrogate oral tolerance, while α/β TCR+ cells provide B cell help. J Exp M. 175:1992;695-707.
22. Holt P.G. Immunoprophylaxis of atopy. Light at the end of the tunnel? Immunol Today. 15:1994;484-489.
23. Wildner G., Hunig T., Thurau S.R. Orally induced, peptide-specific γ/δ TCR+ cells suppress experimental autoimmune uveitis. Eur J Immunol. 26:1996;2140-2148.
24. Shi H.N., Grusby M.J., Nagler-Anderson C. Orally induced peripheral nonresponsiveness is maintained in the absence of functional Th1 or Th2 cells. J Immunol. 162:1999;5143-5148.
25. Trentham D.E. Oral tolerization as a treatment of rheumatoid arthritis. Rheum Dis Clin North Am. 24:1998;525-536.
26. Kalden J.R., Sieper J. Oral collagen in the treatment of rheumatoid arthritis. Arthritis Rheum. 41:1998;191-194.
27. Cleland L.G., Mayrhoffer G. Mucosal tolerance and rheumatoid arthritis. Br J Rheumatol. 36:1997;1139-1143.
28. Marth T., Zeith Z., Ludviksson B., Strober W., Kelsall B. Murine model of oral tolerance. Induction of Fas-mediated apoptosis by blockade of interleukin-12. Ann NY Acad Sci. 859:1998;290-294.
29. Chen Y., Inobe J.I., Kuchro V.K., Baroin J.L., Janeway C.A., Weiner H.L. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci USA. 93:1996;388-391.
30. Samoilova E.B., Horton J.L., Zhang H., Khoury S.J., Weiner H.L., Chen Y. CTLA-4 is required for the induction of high dose oral tolerance. Int Immunol. 10:1998;491-498.
31. Al Sabbagh A.M., Garcia G., Slavin A.J., Weiner H.L., Nelson P.A. Combination therapy with oral myelin basic protein and oral methotrexate enhances suppresion of experimental autoimmune encephalomyelitis [abstract]. Neurology. 48:1997;A421-A421.
32. Nagler-Anderson C., Bober L.A., Robinson M.E., Siskind G.W., Thorbecke J.G. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA. 83:1986;7443-7446.
33. Thorbecke G.J., Schwarcz R., Leu J., Huang C., Simmons W.J. Modulation by cytokines of induction of oral tolerance to type II collagen. Arthritis Rheum. 42:1999;110-118.
34. Thompson H.S.G., Staines N.A. Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats. Clin Exp Immunol. 64:1985;581-586.
35. Khare S.D., Krco C.J., Griffiths M.M., Luthra H.S., David C.S. Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. J Immunol. 155:1995;3653-3659.
36. Myers L.K., Seyer J.M., Stuart M., Kang A.H. Suppression of murine collagen-induced arthritis by nasal administration of collagen. Immunology. 90:1997;161-164.
37. Staines N.A., Harper N., Ward F.J., Malmstrom V., Holmdahl R., Bansal S. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin Exp Immunol. 103:1996;368-375.
38. Thompson H.S.G., Harper N., Bevan D.J., Staines N.A. Suppression of collagen induced arthritis by oral administration of type II collagen: changes in immune and arthritic responses mediated by active peripheral suppression. Autoimmunity. 16:1993;189-199.
39. Zhang H.J., Lee C.S.Y., Lider O., Weiner H.L. Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J Immunol. 145:1990;2489-2493.
40. Yoshino S., Quattrocchi E., Weiner H.L. Suppression of antigen-induced arthritis in Lewis rats by oral administration of type II collagen. Arthritis Rheum. 38:1995;1092-1096.
41. Thompson S.J., Thompson H.S.G., Harper N., Day M.J., Coad A.J., Elson C.J., Staines N.A. Prevention of pristane-induced arthritis by the oral administration of type II collagen. Immunology. 79:1993;152-157.
42. Prakken B.J., Van der Zee R., Anderton S.M., Van Kooten P.J.S., Kuis W., Van Eden W. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. Proc Natl Acad Sci USA. 94:1997;3284-3289.
43. Jorgensen C., Gedon E., Jaquet C., Sany J. Gastric administration of recombinant 65 kDa heat shock protein delays the severity of type II collagen induced arthritis in mice. J Rheumatol. 25:1998;763-767.
44. Chen W., Jin W., Cook M., Weiner H.l, Wahl S.M. Oral delivery of group A streptococcal cell walls augments circulating TGF-β and suppresses streptococcal cell wall arthritis. J Immunol. 161:1998;6297-6304.
45. Wolvers D.A.W., Coenen-De Ro J.J., Mebius R.E., Van der Cammen M.J.F., Tirion F., Miltenburg A.M.M., et al. Intranasally induced immunological tolerance is determined by chatacteristics of the draining lymph nodes : studies with OVA and human cartilage gp-39. J Immunol. 162:1999;1994-1998.
46. Trentham D.E., Dynesius-Trentham R.A., Orav E., Combitchi D., Lorenzo C., Sewel K.L., et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science. 261:1993;1727-1730.
47. Barnett M.L., Kremer J.M., StClair W., Clegg D.o, Furst D., Weisman M., et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 41:1998;290-297.
48. Sieper J., Kary S., Sorensen H., Alter R., Eggens U., Huge W., et al. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum. 39:1996;41-51.
49. Raspe H.H., Kindel P., Vesterling K., Kohlmann T. Die Entwicklung der Funktionskapazität und der Schmerzintensitat von 81 cl-patienten unterliner Behandlung mit Azulfidine RA oder Aurothioglucose. Z Rheumatol. 46:1987;71-75.
50. Barnett M.L., Combitchi D., Trentham D.E. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum. 39:1996;623-628.
51. Gimsa U., Sieper J., Braun J., Mitchison N.A. Type II collagen serology: a guide to clinical responsiveness to oral tolerance? Rheumatol Int. 16:1997;237-240.
52. Daniel D., Wegman D.R. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA. 93:1996;956-960.
53. Joosten L.A.B., Coenen-De Roo C.J.J., Helsen M.M.A., Lubberts E., Boots A.M.H., Van der Berg W.B., Miltenburg A.M.M. Induction of tolerance with intranasal administration of human cartilage gp 39 in DBA/l mice. Arthritis Rheum. 43:2000;654-655.